GLP-1 Pipeline Update: August 2025

As the GLP-1 pipeline continues to grow, Prime actively monitors this emerging landscape and provides a credible clinical snapshot of what is on the horizon. The table below displays the earliest potential approval dates of the agents listed. Dates are based on manufacturer published announcements or communications or are estimated based on study completion dates and may change as more information becomes available.

	Diabetes and diabetes-related conditions					Obesity or overweight and related conditions						Other Conditions	
Drug / dosage form	**T2DM**	**T2DM + CVD**	**T2DM + PAD**	**Diabetic nephropathy**	**Diabetic retinopathy**	**Obesity or overweight**	**Obesity or overweight + CVD**	**OSA + obesity or overweigh**	**OA of knee + obesity or overweight**	**Chronic HF + obesity**	**CKD + obesity or overweight**	**Alzheimer's disease**	**MASH**
Manufacturer: AstraZeneca													
exenatide (Byetta, Bydureon Bcise) / SC	FDA approved (Byetta *only* ages ≥ 10 years)												
Manufacturer: Eli Lilly													
dulaglutide (Trulicity) / SC	FDA approved (ages ≥ 10 years)	FDA approved											
tirzepatide (Mounjaro) / SC	FDA approved for adults; *FDA decision in 2026 for pediatric & adolescent T2DM*	2026											
tirzepatide (Zepbound) / SC						FDA approved		FDA approved			2027		
orforglipron / oral	2027					2026		2027					
retatrutide / SC	2027			2027		2027	2027		2027				
Manufacturer: Novo Nordisk													
liraglutide (Victoza)* / SC	FDA approved (ages ≥ 10 years)	FDA approved											

© 2025 Prime Therapeutics LLC

Drug / dosage form	T2DM	T2DM + CVD	T2DM + PAD	Diabetic nephropathy	Diabetic retinopathy	Obesity or overweight	Obesity or overweight + CVD	OSA + obesity or overweigh	OA of knee + obesity or overweight	Chronic HF + obesity	CKD + obesity or overweight	Alzheimer's disease	MASH
Manufacturer: Novo Nordisk (cont.)													
liraglutide (Saxenda)* / SC						FDA approved (ages ≥ 12 years)							
liraglutide-insulin degludec (Xultophy) / SC	FDA approved												
semaglutide (Rybelsus) 1.5–14 mg / oral	FDA approved	*FDA decision Oct. 2025*										2027	
semaglutide 25 mg (Wegovy) / oral						*FDA decision 4Q2025*	*FDA decision 4Q2025*						
semaglutide 25 mg, 50 mg (NN9924) / oral	2026												
semaglutide 1 mg, 2 mg (Ozempic) / SC	FDA approved	FDA approved	*FDA decision 4Q2025*	FDA approved	2027								
semaglutide 1.7 mg, 2.4 mg (Wegovy) / SC						FDA approved (ages ≥ 12 years)	FDA approved		2026	*FDA decision 2H2025*			FDA approved
semaglutide-insulin icodec / SC	2026												
cagrilintide-semaglutide / SC	2027					2027							
Manufacturer: Sanofi													
lixisenatide-insulin glargine (Soliqua) / SC	FDA approved												
Manufacturer: Zealand, Boehringer Ingelheim													
survodutide / SC						2027	2027						

*generics available

Glossary

CKD = chronic kidney disease
CVD = cardiovascular disease
FDA = Food and Drug Administration
GLP-1 = glucagon-like peptide-1 receptor agonist
HF = heart failure
MASH = metabolic dysfunction-associated steatohepatitis
OA = osteoarthritis
OSA = obstructive sleep apnea
PAD = peripheral arterial disease
SC = subcutaneous
T2DM = type 2 diabetes mellitus

Disclaimer

The drug pipeline is fluid; the dates and information within this publication are subject to change. Nothing herein is or shall be construed as a promise or representation regarding past or future events and Prime Therapeutics expressly disclaims any and all liability relating to the use of or reliance on the information contained in this presentation. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to or disclosed to others at any time without the prior written consent of Prime Therapeutics.

All brand names are property of their respective owners.